Equities Analysts Offer Predictions for XFOR Q3 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at Brookline Capital Markets increased their Q3 2026 EPS estimates for X4 Pharmaceuticals in a research note issued to investors on Thursday, August 6th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of ($0.22) per share for the quarter, up from their prior forecast of ($0.24). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.77) per share. Brookline Capital Markets also issued estimates for X4 Pharmaceuticals’ FY2026 earnings at ($0.79) EPS, FY2028 earnings at ($0.26) EPS and FY2030 earnings at $3.29 EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 64.95%. The firm had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million.

Several other research firms also recently commented on XFOR. Wells Fargo & Company initiated coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective for the company. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Finally, Leerink Partners started coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.70.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $4.25 on Tuesday. The company has a market cap of $400.86 million, a PE ratio of -3.54 and a beta of 0.37. The stock’s 50 day simple moving average is $4.03 and its 200-day simple moving average is $3.95. X4 Pharmaceuticals has a 1-year low of $1.35 and a 1-year high of $4.83. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.18 and a quick ratio of 9.98.

Institutional Trading of X4 Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Pettinga Financial Advisors LLC acquired a new position in X4 Pharmaceuticals in the second quarter valued at approximately $47,000. Indivisible Partners purchased a new stake in X4 Pharmaceuticals in the fourth quarter valued at $40,000. SummitTX Capital L.P. acquired a new position in shares of X4 Pharmaceuticals in the 1st quarter valued at $46,000. Squarepoint Ops LLC purchased a new position in shares of X4 Pharmaceuticals during the 4th quarter worth $50,000. Finally, Two Sigma Investments LP purchased a new stake in X4 Pharmaceuticals in the 3rd quarter valued at about $47,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

Insider Activity

In related news, CFO David Kirske sold 8,543 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the sale, the chief financial officer directly owned 167,750 shares in the company, valued at approximately $714,615. This trade represents a 4.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.13% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.